RecruitingPhase 1NCT06942143

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors

Sponsor

Guangzhou FineImmune Biotechnology Co., LTD.

Enrollment

15 participants

Start Date

May 22, 2025

Study Type

INTERVENTIONAL

Conditions

Lung Cancers Sarcoma Melanoma

Summary

This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria25

Sign informed consent before conducting any trial-related activities;
Age of 18-75 years old, male or female;
Patients with first-line treatment failure;
Measurable lesions according to RECIST1.1 criteria.
During the trial screening period, the following two screening criteria must be met (by the sponsor) :
HLA-A\*02 positive;
The positive rate of NYESO-1 immunohistochemical staining was ≥20%.
ECOG score 0-1;
The expected survival time is more than 3 months;
Antineoplastic drugs and treatments were not allowed for 4 weeks before TCR-T cell infusion;
Echocardiography showed left ventricular ejection fraction ≥50%;
Laboratory test results should at least meet the following specified indicators:
WBC ≥3.0×109/L;
Absolute neutrophil count (ANC) ≥1.5×109/L;
Absolute lymphocyte count (ALC) ≥1.0×109/L;
platelet (PLT) ≥75×109/L;
hemoglobin ≥10g/dL (no blood transfusion in the past 7 days);
Prothrombin time or INR≤1.5x upper limit of normal unless receiving anticoagulant therapy;
Partial prothrombin time (APTT) ≤1.5x upper limit of normal time, unless receiving anticoagulant therapy;
hour creatinine clearance ≥60mL/ min;
Aspartate aminotransferase (AST/SGOT) ≤2.5×ULN;
alanine aminotransferase (ALT/SGPT) ≤2.5×ULN;
Total bilirubin (TBIL) ≤1.5×ULN
Negative pregnancy tests in women of childbearing potential prior to study treatment; Consent must be given to use effective contraception during treatment.
During the whole period of the trial, I can regularly visit the enrolled research institutions for relevant testing, evaluation and management.

Exclusion Criteria14

Patients who received major surgery, conventional chemotherapy, large area radiotherapy, immunotherapy or biological therapy within 4 weeks before entering the trial;
Known to produce allergic reactions to any component of the trial treatment;
no recovery from previous surgery or treatment-related adverse events to ≤ grade 2 CTCAE;
Poorly controlled hypertension (systolic blood pressure \> 160mmHg and/or diastolic blood pressure \> 90mmHg) or clinically significant (e.g., active) cardio-cerebrovascular disease; Cerebrovascular accident (within 6 months before the signing of informed consent), myocardial infarction (within 6 months before the signing of informed consent), unstable angina, congestive heart failure of New York Heart Association class II or higher (Appendix), or severe arrhythmia that could not be controlled with medications or that had the potential to affect study treatment; Electrocardiogram (ECG) was significantly abnormal or the mean QTc interval was ≥450 msec on three consecutive occasions.
Combined with other serious organic diseases and mental disorders;
Have active systemic infection requiring treatment, including active tuberculosis, known HIV positivity, or clinically active hepatitis A, B, or C; (Virus carriers should be excluded)
Patients with autoimmune diseases: those with a history of inflammatory bowel disease or a history of autoimmune diseases (such as systemic lupus erythematosus, vasculitis, and invasive lung disease) judged by the investigators to be not suitable for this study should be excluded; (Patients with vitiligo are not excluded).
Administration of chronic systemic cortisone steroids, hydroxyurea, and immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy."
History of organ transplantation, autologous/allogeneic stem cell transplantation and renal replacement therapy;
Known uncontrolled diabetes mellitus, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure;
Known alcohol and/or drug abuse;
Pregnant or lactating women;
Trial participants with any coexisting medical conditions or diseases judged by the investigators to be likely to impair the conduct of the trial;
No legal capacity/limited capacity.

Interventions

BIOLOGICALSuper1 TCR-T

All participators received lymphoid-depleted preconditioning before Super1 TCR-T cells infusion. Super1 TCR-T cells were infused 3 days later. Concomitant administration of interleukin for 7 consecutive days.

Locations(1)

Sun Yat-sen University Cancer Center

Guangzhou, Gaungdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06942143

Related Trials

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

NCT06418204467 locations

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT0711504311 locations